Showing 2461-2470 of 9821 results for "".
RIP Clarisonic, Hello New Contenders
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/rip-clarisonic-hello-new-contenders/23354/CSF faculty share top picks for at-home beauty devices.Management of Atopic Dermatitis During the COVID-19 Pandemic
https://practicaldermatology.com/topics/atopic-dermatitis/management-of-atopic-dermatitis-during-the-covid-19-pandemic/23322/There is concern about the immunosuppressive or immunomodulatory effects of oral and biologic medications in patients with skin disease.DermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlookFacing Challenges: Adapting Practice in the Face of COVID-19
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/facing-challenges-adapting-practice-in-the-face-of-covid-19/23266/CSF Faculty share experiences and tips for practicing in the “new normal.”Pigmentation Disorders
https://practicaldermatology.com/topics/pigmentary-disorders/pigmentation-disorders/19730/Sunscreen may be the first, second, and third thing recommended for patients with pigmentation disorders, but what comes next? Joel Cohen, MD interviews Amit Pandya, MD to learn about treatment options and developments in the pipeline.DermWire TV: Merz Reorganizes; Amzeeq Approved; Restoration Merges with Venus Concept
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-merz-reorganizes-amzeeq-approved-restoration-merges-with-venus-concept/19694/Bob Rhatigan, newly appointed Global Chief Executive Officer of Merz Aesthetics, speaks about Merz reorganization. Amzeeq topical foam (Foamix Pharmaceuticals) approved for inflammatory, non-nodular, moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. FDA acAtopic Dermatitis: Understanding the Impact
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-understanding-the-impact/19667/For most AD patients, eczema is a bumpy ride. Even mild cases of atopic dermatitis can have a significant effect on people—and these effects range from quality of life impact to treatment costs. Peter Lio, MD describes his approach to a long-term eczema management plan.Isotretinoin Updates 2019
https://practicaldermatology.com/topics/acne-rosacea/isotretinoin-updates-2019/23080/One of the best studied medications for treating acne, isotretinoin can deliver high rates of lasting cures with predictable side effect profiles. Here’s an update on the latest in patient management.Benefits and Challenges of Medical Practice Types
https://practicaldermatology.com/topics/practice-management/benefits-and-challenges-of-medical-practice-types/23058/As medicine in general and dermatology specifically shifts toward more employed physicians, it’s important to understand the options.Get to Know DataDerm
https://practicaldermatology.com/topics/practice-management/get-to-know-dataderm/22067/Practical Dermatology® gets the inside scoop on the AAD's data registry from Marta Van Beek, MD.